

INCREASED RISK OF CARDIAC DEATH AFTER THERAPY FOR HODGKIN'S DISEASE

To the Editor:

Dr Mauch presents a thorough and balanced clinical review on the management of patients with early stage Hodgkin's disease.¹ However, an error was made in reporting the results of a Stanford study assessing intercurrent death after Hodgkin's disease therapy.² This error was made by the authors of that series and reported later in a correction.³ The relative risk of death from a malignancy other than Hodgkin's disease was 9.3 (confidence interval (CI), 5.9 to 12.9; $P < .01$) and that for death from acute myocardial infarction was 3.2 (CI, 1.5 to 5.8; $P < .01$), both higher than originally reported. Thus, the Stanford series is actually in agreement with the report by Boivin⁴ cited in the review.

Ted Wun
*Division of Hematology and Oncology
University of California, Davis*

REFERENCES

1. Mauch, PM: Controversies in the management of early stage Hodgkin's disease. *Blood* 83:318, 1994
2. Hancock SL, Hoppe RT, Horning SJ, and Rosenberg SA: Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials. *Ann Int Med* 109:183, 1988
3. Hancock SL, Cox RS, Rosenberg SA: Correction: Deaths after treatment of Hodgkin disease. *Ann Int Med* 114:810, 1991
4. Boivin J-F, Hutchison G, Lubin J, Mauch P: Coronary artery disease mortality in patients treated for Hodgkin's disease. *Cancer* 69:1241, 1992